Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma (original) (raw)

• Stevenson, G.T. & Stevenson, F.K. Antibody to molecularly-defined antigen confined to a tumor cell surface. Nature 254, 714–716 ( 1975).
  Article CAS Google Scholar
• Lynch, R.G. et al. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA 69, 1540– 1544 (1972).
  Article CAS Google Scholar
• Kwak, L.W. et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209–1215 (1992).
  Article CAS Google Scholar
• Hsu, F.J. et al. Tumor-specific idiotype vaccines in the treatment of patients with B-Cell lymphoma–Long term results of a clinical trial. Blood 89, 3129–3135 ( 1997).
  CAS Google Scholar
• Greenberg, P.D. Adoptive T-cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281–355 (1991).
  Article CAS Google Scholar
• Shu, S., Chou T. & Rosenberg, S.A. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J. Immunol. 139, 295–304 (1987).
  CAS PubMed Google Scholar
• Kwak, L.W., Young, H.A., Pennington, R.W. & Weeks, S.D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte-macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 93, 10972–10977 (1996).
  Article CAS Google Scholar
• Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539–3543 ( 1993).
  Article CAS Google Scholar
• Lee, M.S. et al. Detection of minimal residual disease carrying the t(14;18) by DNA sequence amplification. Science 237, 175–178 (1987).
  Article CAS Google Scholar
• Gribben, J.G. et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78, 3275–3280 ( 1991).
  CAS PubMed Google Scholar
• Cortopassi, G.A. & Arnheim, N. Using the polymerase chain reaction to estimate mutation frequencies and rates in human cells. Mutat. Res. 277, 239–249 (1992).
  Article CAS Google Scholar
• Rosenberg, S.A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 3, 321–327 ( 1998).
  Article Google Scholar
• Correale, P. et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. 89, 293–300 (1997).
  Article CAS Google Scholar
• Mandruzzato, S., Brasseur, F., Andry, G., Boon, T. & van der Bruggen, P. A. CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186 , 785–793 (1997).
  Article CAS Google Scholar
• Kato, K., Cantwell, M.J., Sharma, S. & Kipps, T.J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J. Clin. Invest. 101, 1133–1141 (1998).
  Article CAS Google Scholar
• Nair, S.K. et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16, 364– 369 (1998).
  Article CAS Google Scholar
• Brossart, P. et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer. Res. 58, 732–736 (1998).
  CAS PubMed Google Scholar
• Kim, H.T. et al. γδ T cell recognition of tumor Ig peptide. J. Immunol. 154, 1614–1623 (1995).
  CAS PubMed Google Scholar
• Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52–58 (1996).
  Article CAS Google Scholar
• Kwak, L.W. et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 345, 1016 –1020 (1995).
  Article CAS Google Scholar
• Osterborg, A. et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted CD8- and CD4-specific T-cell response. Blood 91, 2459–2466 ( 1998).
  CAS PubMed Google Scholar
• Raffeld, M., Neckers, L., Longo, D.L. & Cossman, J. Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by an anti-idiotype. N. Engl. J. Med. 312, 1653– 1658 (1985).
  Article CAS Google Scholar
• Meeker, T. et al. Emergence of idiotype variants during treatment with anti-idiotype antibodies. N. Engl. J. Med. 312, 1658– 1665 (1985).
  Article CAS Google Scholar
• Lopez-Guillermo, A. et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 91, 2955– 2960 (1998).
  CAS PubMed Google Scholar
• Grabbe, S., Beissert, S., Schwarz, T. & Granstein, R.D. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today 16, 117–120 (1995).
  Article CAS Google Scholar
• Nelson, E.L. et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88, 580–589 (1996).
  CAS PubMed Google Scholar
• Fisher, R.I. et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann. Intern. Med. 98, 304–309 ( 1983).
  Article CAS Google Scholar
• Kobrin, C.B. & Kwak, L.W. Development of vaccine strategies for the treatment of B-cell malignancies. Cancer Invest. 15, 577–587 (1997).
  Article CAS Google Scholar
• Schultze, J.S. et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. Sci. USA 92, 8200– 8204 (1995).
  Article CAS Google Scholar
• Schultze, J.S., Seamon, M.J., Michalak, S., Gribben, J.G. & Nadler, L.M. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro . Blood 89, 3806–3816 (1997).
  CAS PubMed Google Scholar
• Wiltrout, R.H., Taramelli, D. & Holden, H.T. Measurement of macrophage-mediated cytotoxicity against adherent and non-adherent target cells by release of 111Indium-oxine. J. Immunol. Meth. 43, 319– 331 (1981).
  Article CAS Google Scholar